Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy.

Disease Sites:

Lung

Staging:

Phase III

Age Group:

Adults

Therapies:

Not Available

Drugs:

Docetaxel (Taxotere), N-803, Tislelizumab

Principal Investigator(s):

Lovly, Christine

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

09-30-2025

Trial Type:

Treatment

Protocol ID:

VICCTHO24569

National Clinical Trial ID:

NCT06745908

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available